It is three IND's, not two! "This is the first observation that a neurotrophic factor is able to rescue retinal function after significant insult," said David A. Lowe, PhD, President & CEO of NeuroAssets and member of the Amarantus Board of Directors. "These data clearly support our focus on the further development of MANF in orphan ophthalmic indications, such as retinitis pigmentosa and CRVO. We plan to pursue complementary IND pathways in these indications, as well as in glaucoma."
MANF is continuing to show incredible healing powers and is going to launch AMBS onto a National Exchange very soon. AMBS may become the next MEGA Biotech in our lifetime. Yes, nice job Gerald, "Just Do It!!"